Smoking Cessation in Patients With Cancer
Effectiveness of a Cognitive Behavioral Therapy-Based Smoking Cessation Intervention Among Patients With Cancer at a Hospital in Vietnam
1 other identifier
interventional
446
1 country
1
Brief Summary
This randomized controlled trial will evaluate whether adding one-session structured cognitive behavioral therapy (CBT)-based smoking-cessation counseling to standardized brief smoking-cessation counseling improves cigarette smoking abstinence among patients with cancer who smoked combustible cigarettes at diagnosis and are still smoking at screening and enrollment. After written informed consent and baseline assessment, all participants will receive the same standardized brief smoking-cessation counseling using a condensed 5A framework. Participants will then be randomly assigned 1:1 to no additional study CBT or to one additional structured CBT-based smoking-cessation session. Follow-up will continue for 3 months after randomization at Campus 3 of Vietnam National Cancer Hospital in Hanoi, Vietnam.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable cancer
Started Oct 2026
Shorter than P25 for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 10, 2026
CompletedFirst Posted
Study publicly available on registry
September 16, 2026
CompletedStudy Start
First participant enrolled
October 15, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2027
Study Completion
Last participant's last visit for all outcomes
July 15, 2027
September 16, 2026
September 1, 2026
9 months
September 10, 2026
September 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Self-Reported 7-Day Point-Prevalence Cigarette Smoking Abstinence at 3 Months
7-day point-prevalence cigarette smoking abstinence will be defined as self-report of no cigarette smoking, not even a puff, during the 7 days preceding the 3-month follow-up assessment. Participants reporting any cigarette smoking, even a puff, during this 7-day period will be classified as not abstinent. No biochemical verification.
3 months after randomization
Secondary Outcomes (4)
Self-Reported 7-Day Point-Prevalence Cigarette Smoking Abstinence at 1 and 2 Months
1 and 2 months after randomization.
: Self-Reported Sustained Cigarette Smoking Abstinence From Month 1 Through Month 3.
From 1 month through 3 months after randomization
At least one intentional quit attempt lasting ≥24 hours during the 3-month follow-up.
From randomization through 3 months
Readiness/Commitment to Quit Cigarette Smoking
Baseline and 1, 2, and 3 months after randomization
Study Arms (2)
Standardized Brief Smoking-Cessation Counseling Alone
ACTIVE COMPARATORBefore randomization, all participants receive the same individual face-to-face standardized brief smoking-cessation counseling session lasting approximately 3-5 minutes using a condensed 5A framework. After randomization, participants allocated to the control arm receive no additional study CBT. Study outcome follow-up is identical in both arms.
Standardized Brief Smoking-Cessation Counseling Plus Structured CBT
EXPERIMENTALBefore randomization, all participants receive the same standardized brief 5A smoking-cessation counseling. After randomization, participants allocated to the intervention arm are offered one additional individual structured CBT-based smoking-cessation counseling session lasting approximately 20-30 minutes. Declining CBT after randomization does not change randomized assignment; follow-up continues if the participant agrees.
Interventions
Common pre-randomization care delivered to all enrolled participants after consent and baseline assessment and before allocation is revealed. One individual face-to-face session lasting approximately 3-5 minutes using a condensed 5A framework (Ask, Advise, Assess, Assist, Arrange).
Only participants randomized to the intervention arm are offered one additional individual face-to-face CBT-based smoking-cessation session lasting approximately 20-30 minutes after allocation. Six modules address smoking-related cognitions/beliefs, cognitive restructuring, individualized quit goal/date/plan, triggers/high-risk situations, coping for cravings/withdrawal/stress, and relapse-prevention/lapse management. Delivery is standardized and fidelity is recorded.
Eligibility Criteria
You may qualify if:
- Aged 18 years or older.
- Diagnosed with cancer.
- Was smoking combustible cigarettes at the time of cancer diagnosis.
- Still smoking combustible cigarettes at screening/enrollment.
- Able to communicate sufficiently and provide reliable study information.
- Provides written informed consent.
You may not qualify if:
- Clinically too severe for reliable participation.
- Cognitive/communication limitations precluding consent or reliable participation.
- Currently participating in a competing structured smoking-cessation program.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nguyen Duc Khoa, MD, PhDlead
- Vietnam Tobacco Control Fundcollaborator
Study Sites (1)
Vietnam National Cancer Hospital
Hanoi, 100000, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nguyen Duc Khoa, MD, PhD
Vietnam National Cancer Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDIV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Director of Center for Training and Technical Transfer
Study Record Dates
First Submitted
September 10, 2026
First Posted
September 16, 2026
Study Start (Estimated)
October 15, 2026
Primary Completion (Estimated)
July 15, 2027
Study Completion (Estimated)
July 15, 2027
Last Updated
September 16, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will share
De-identified individual participant data underlying reported results may be made available upon reasonable request, subject to ethical requirements, institutional approval, and a data-sharing agreement.